Overview
Calidi Biotherapeutics develops clinical-stage oncolytic virotherapies and stem cell-based platforms for treating solid tumors and metastatic cancers. Their RedTail platform enables systemic delivery of engineered enveloped viruses like CLD-401, which express IL-15 superagonists to activate anti-tumor immunity. NeuroNova programs, such as CLD-101, use neural stem cells to deliver oncolytic adenoviruses selectively to high-grade gliomas.
Frequently asked questions
- What are Calidi's main therapeutic platforms?
- Calidi's RedTail platform delivers systemic oncolytic viruses for metastatic solid tumors, while NeuroNova uses neural stem cells to carry oncolytic viruses to brain tumors like high-grade gliomas.
- What is the clinical status of their programs?
- CLD-101 is in Phase 1 trials for recurrent high-grade glioma, with first patient dosed. CLD-401 from RedTail is advancing with preclinical data presented at ASCO.
- What tumor types do they target?
- Targets include high-grade gliomas, lung cancer, and over 60 tumor cell lines, focusing on advanced metastatic solid tumors.